Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. by Ferreira, João Pedro et al.
Listen to this manuscript’s
audio summary by
Editor-in-Chief
Dr. Valentin Fuster on
JACC.org.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 7 7 , N O . 1 1 , 2 0 2 1
ª 2 0 2 1 T H E A U T HO R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F OU N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .Interplay of Mineralocorticoid Receptor
Antagonists and Empagliflozin in
Heart Failure
EMPEROR-ReducedJoão Pedro Ferreira, MD,a Faiez Zannad, MD,a Stuart J. Pocock, PHD,b Stefan D. Anker, MD,c Javed Butler, MD,d
Gerasimos Filippatos, MD,e Martina Brueckmann, MD,f,g Waheed Jamal, MD,f Dominik Steubl, MD,f













MaBACKGROUND Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favor-
ably influence the clinical course of patients with heart failure and reduced ejection fraction.
OBJECTIVES This study sought to study the mutual influence of empagliflozin and MRAs in EMPEROR-Reduced
(Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction).
METHODS Secondary analysis that compared the effects of empagliflozin versus placebo in 3,730 patients with heart
failure and a reduced ejection fraction, of whom 71% used MRAs at randomization.
RESULTS The effects of empagliflozin on the primary endpoint, on most efficacy endpoints, and on safety were similar
in patients receiving or not receiving an MRA (interaction p > 0.20). For cardiovascular death, the hazard ratios for the
effect of empagliflozin versus placebo were 0.82 (95% confidence interval [CI]: 0.65 to 1.05) in MRA users and 1.19
(95% CI: 0.82 to 1.71) in MRA nonusers (interaction p ¼ 0.10); a similar pattern was seen for all-cause mortality
(interaction p ¼ 0.098). Among MRA nonusers at baseline, patients in the empagliflozin group were 35% less likely than
those in the placebo group to initiate treatment with an MRA following randomization (hazard ratio: 0.65; 95% CI: 0.49
to 0.85). Among MRA users at baseline, patients in the empagliflozin group were 22% less likely than those in the
placebo group to discontinue treatment with an MRA following randomization (hazard ratio: 0.78; 95% CI: 0.64 to
0.96). Severe hyperkalemia was less common in the empagliflozin group.
CONCLUSIONS In EMPEROR-Reduced, the use of MRAs did not influence the effect of empagliflozin to reduce adverse
heart failure and renal outcomes. Treatment with empagliflozin was associated with less discontinuation of MRAs.
(Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction [EMPEROR-
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ABBR EV I A T I ON S
AND ACRONYMS
CI = confidence interval
eGFR = estimated glomerular
filtration rate




NT-proBNP = N-terminal pro–
B-type natriuretic peptide
NYHA = New York Heart
Association
SGLT2 = sodium glucose co-
transporter 2
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1398M ineralocorticoid receptor antago-nists (MRAs) reduce the mor-bidity and mortality of patients
with heart failure and reduced ejection frac-
tion. The EMPHASIS-HF (Eplerenone in Mild
Patients Hospitalization and Survival Study
in Heart Failure) and RALES (Randomized
Aldactone Evaluation Study) trials demon-
strated that both eplerenone and spironolac-
tone decreased the risk of cardiovascular
death and the risk of hospitalization for heart
failure in patients with mild and moderate to
severe symptoms, respectively (1,2).
More recently, the DAPA-HF (Dapagliflozin
and Prevention of Adverse Outcomes inHeart Failure) trial and the EMPEROR-Reduced
(Cardiovascular and Empagliflozin Outcome Trial in
Patients with Chronic Heart Failure and a Reduced
Ejection Fraction) showed that the sodium glucose
co-transporter 2 (SGLT2) inhibitors dapagliflozin and
empagliflozin reduced the composite risk of cardio-
vascular death or hospitalization for heart failure in
patients with heart failure and a reduced ejection
fraction, with and without diabetes, with similar ef-
fects in patients receiving or not receiving an MRA
before randomization (3–5). However, it is not clear
how MRAs influence other measures of efficacy (as
well as the safety) of SGLT2 inhibitors and whether
SGLT2 inhibition may influence the utilization of
MRAs.
In this secondary analysis of EMPEROR-Reduced,
we examined the influence of MRA use at baseline
on the efficacy and safety of empagliflozin and
whether empagliflozin influenced the prescribing of
MRAs following randomization.SEE PAGE 1408METHODS
EMPEROR-Reduced was a randomized, double-blind,
parallel-group, placebo-controlled, and event-driven
study, the design of which has been described pre-
viously (4). Participants were men or women with
chronic heart failure (functional class II, III, or IV)
with a left ventricular ejection fraction of #40% who
were receiving appropriate background treatment for
heart failure. We preferentially enrolled patients with
an ejection fraction of #30% by requiring those with a
higher ejection fraction to have been hospitalized for
HF within 12 months or to have markedly increased
levels of N-terminal pro–B-type natriuretic peptide
(NT-proBNP), that is, $1,000 pg/ml or $2,500 pg/ml
in those with an ejection fraction of 31% to 35% or
36% to 40%, respectively; these thresholds weredoubled in patients with atrial fibrillation. The ethics
committee of each of the 520 sites in 20 countries
approved the protocol, and all patients gave written
informed consent.
RANDOMIZATION. Patients were randomized in a
double-blind manner (in a 1:1 ratio) to receive placebo
or empagliflozin 10 mg daily, in addition to their usual
therapy. The use of MRAs at baseline was not
a stratification variable. Following entry into the
trial, all appropriate treatments for heart failure or
other medical conditions (including MRAs) could be
initiated, discontinued, or altered at the clinical
discretion of the investigator. Patients were periodi-
cally assessed at study visits for major outcomes,
symptoms, and functional capacity related to heart
failure, initiation or discontinuation of new treat-
ments for heart failure (including MRAs), vital signs
and biomarkers reflecting changes in the course of
heart failure or the action of SGLT2 inhibitors,
and adverse events. All randomized patients were
followed for the occurrence of pre-specified outcomes
for the entire duration of the trial, regardless of
whether the study participants were taking their study
medications or adhered to the schedule of study visits.
TRIAL ENDPOINTS. The primary endpoint was the
composite of adjudicated cardiovascular death hos-
pitalization for heart failure, analyzed as the time to
first event. The first secondary endpoint was the
occurrence of all adjudicated hospitalizations for
heart failure (including first and recurrent events).
The second secondary endpoint was the analysis of
the slope of the change in estimated glomerular
filtration rate (eGFR) during double-blind treatment,
which was supported by an analysis of a composite
of serious adverse renal events, defined by the
need for chronic dialysis or renal transplant, or a
sustained $40% drop in eGFR, or a sustained eGFR
of <15 ml/min/1.73 m2 (if the baseline eGFR
was $30 ml/min/1.73 m2) or <10 ml/min/1.73 m2 (if
the baseline eGFR was <30 ml/min/1.73 m2). Addi-
tional analyses included the individual components
of the primary endpoint as well as all-cause mortality,
health status as assessed by the Kansas City Cardio-
myopathy Questionnaire (KCCQ), systolic blood
pressure, body weight, and laboratory parameters.
The pre-specified safety analyses included serious
adverse events, adverse events associated with
discontinuation of a trial treatment, and adverse
events of special interest (i.e., volume depletion,
renal events, and hypotension). The occurrence of
a serum potassium concentration of >5.5 mmol/l
and >6.0 mmol/l as well as investigator-reported
hyperkalemia were also analyzed.
TABLE 1 Clinical Characteristics, According to the Use of an MRA at Baseline





(n ¼ 2,661) p Value
Age, yrs 69.6  10.5 65.7  11.1 <0.0001
Women 238 (22.3) 655 (24.6) 0.13
Race
White 727 (67.7) 1905 (71.6) 0.003
Black 81 (7.6) 176 (6.6)
Asian 226 (21.1) 446 (16.8)
Other/missing 38 (3.5) 134 (5.1)
Region
North America 215 (20.1) 210 (7.9) <0.0001
Latin America 254 (23.8) 1032 (38.8)
Europe 378 (35.4) 975 (36.6)
Asia 169 (15.8) 324 (12.2)
Other 53 (5.0) 120 (4.5)
Body mass index, kg/m2 27.5  5.3 28.0  5.4 0.013
Heart rate, beats/min 71.3  11.8 71.2  11.7 0.85
Systolic blood pressure, mm Hg 125.1  16.1 120.7  15.3 <0.0001
NYHA functional class
II 815 (76.2) 1985 (74.6) 0.29
III–IV 254 (23.6) 676 (25.4)
Duration of heart failure, yrs 4.2 (1.6–9.2) 3.9 (1.4–8.7) 0.35
Left ventricular ejection fraction, % 28.4  6.0 27.1  6.0 <0.0001
NT-proBNP, pg/ml* 2,015 (1,192–3,814) 1,866 (1,077–3,349) 0.0038
Medical history
Heart failure hospitalization within
12 months
284 (26.6) 867 (32.6) 0.0003
Coronary artery disease 543 (50.8) 1167 (43.9) 0.0001
CABG/PCI 495 (46.3) 1028 (38.6) <0.0001
Atrial fibrillation/flutter 455 (42.6) 986 (37.1) 0.0018
Hypertension 815 (76.2) 1883 (70.8) 0.0007
Diabetes 556 (52.0) 1300 (48.9) 0.081
Clinical and laboratory assessments
HbA1c, % 6.6  1.3 6.6  1.5 0.99
eGFR, ml/min/1.73 m2 57.3  21.0 63.9  21.6 <0.0001
KCCQ clinical summary score 71.9  21.4 70.2  22.2 0.034
Serum potassium, mmol/l 4.6  0.5 4.7  0.5 <0.0001
Heart failure medications
Loop diuretics 840 (78.6) 2310 (86.8) <0.0001
ACE inhibitor 453 (42.4) 1250 (47.0) 0.011
ARB without neprilysin inhibitor 276 (25.8) 632 (23.8) 0.18
Sacubitril/valsartan 190 (17.8) 537 (20.2) 0.093
Beta-blocker 1005 (94.0) 2528 (95.0) 0.22
Devices for heart failure
Implantable cardioverter-defibrillator† 368 (34.4) 803 (30.2) 0.012
Cardiac resynchronization therapy‡ 149 (13.9) 293 (11.0) 0.012
Values are mean  SD, n (%), or median (interquartile range). *Values for NT-proBNP were log transformed.
†Includes all patients with an implantable cardioverter-defibrillator regardless of the presence or absence of
cardiac resynchronization therapy. ‡Includes all patients who were receiving cardiac resynchronization therapy
regardless of the presence or absence of a defibrillator.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor blocker; CABG ¼ coronary artery bypass
grafting; eGFR ¼ estimated glomerular filtration rate; HbA1c ¼ glycated hemoglobin A1c; KCCQ ¼ Kansas City
Cardiomyopathy Questionnaire; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal pro–B-
type natriuretic peptide; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention.
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1399STATISTICAL ANALYSIS. Baseline characteristics
were compared in MRA users and nonusers by using
the chi-square test for categorical variables and
Student’s t-test for continuous variables. For time-to-
first-event analyses, differences between the placebo
and empagliflozin groups were assessed by using a
Cox proportional hazards model with pre-specified
baseline covariates of age, sex, geographic region,
diabetes, left ventricular ejection fraction, and eGFR.
For the analysis of total (first and repeated) events,
the differences between the placebo and empagli-
flozin groups were assessed by using a joint frailty
model, with cardiovascular death (for recurrent
heart failure hospitalizations) or all-cause mortality
(for recurrent hospitalization for any reason) as
competing risks. For the analysis of changes in
vital signs and laboratory measurements, treatment
effects were assessed based on changes from baseline
by using a mixed model for repeated measures.
Between-group differences in the slope of change in
eGFR were analyzed based on data on double-blind
treatment and using a random intercept random
slope model. All analyses used the same covariates as
in the Cox model and included the baseline variable
as an additional covariate, where applicable. For all
efficacy measures, separate analyses were performed
according to the use or nonuse of MRAs at baseline,
and differences in the effect of empagliflozin in users
and nonusers were assessed by interaction terms.
Analyses of safety were performed based on all pa-
tients who had received at least 1 dose of the study
medication. The p values and 95% confidence in-
tervals (CIs) presented in this report have not been
adjusted for multiplicity, and therefore, inferences
drawn from these statistics may not be reproducible.
All analyses were performed with SAS, version 9.4
(SAS Institute, Cary, North Carolina).
DATA SHARING. Data will be made available upon
request in adherence with transparency conventions
in medical research and through requests to the cor-
responding author. The executive committee of EM-
PEROR has developed a comprehensive analysis plan
and numerous pre-specified analyses, which will be
presented in future scientific meetings and publica-
tions. At a later time point, the full database will be
made available in adherence with the transparency
policy of the sponsor.
RESULTS
In EMPEROR-Reduced, 71% of patients were treated
with an MRA at the time of randomization. In general,
MRA users were younger with better renal function
but with a lower ejection fraction, systolic bloodpressure, and NT-pro BNP. Additionally, MRA users
were more likely to have been hospitalized for heart
failure within 12 months and be treated with a loop
diuretic, but they were less likely to have received a
TABLE 2 Effect of Empagliflozin on Pre-Specified Measures of Efficacy, According to the Use of MRAs at Baseline















Cardiovascular death or heart failure hospitalization 132 (25.8) 118 (21.2) 0.76 (0.59–0.97) 330 (24.4) 243 (18.6) 0.75 (0.63–0.88) 0.93
Total number of heart failure hospitalizations 165 126 0.69 (0.48–0.97) 388 262 0.71 (0.56–0.89) 0.88
Slope of decline in eGFR, ml/min/1.73 m2/yr –2.74  0.43 –0.55  0.40 2.19 (1.04–3.35) –2.09  0.27 –0.55  0.28 1.55 (0.79–2.30) 0.36
Composite kidney endpoint 12 (2.3) 11 (2.0) 0.80 (0.35–1.82) 46 (3.4) 19 (1.5) 0.41 (0.24–0.71) 0.18
Time to first hospitalization for heart failure 106 (20.7) 82 (14.7) 0.65 (0.49–0.87) 236 (17.4) 164 (12.6) 0.71 (0.58–0.87) 0.66
Cardiovascular death 51 (10.0) 67 (12.0) 1.19 (0.82–1.71) 151 (11.1) 120 (9.2) 0.82 (0.65–1.05) 0.10
All-cause mortality 68 (13.3) 87 (15.6) 1.15 (0.84–1.59) 198 (14.6) 162 (12.4) 0.84 (0.68–1.03) 0.098
Change in KCCQ clinical summary score at 52 weeks
Increase of >5* 227 (44.3) 292 (52.5) 1.39 [1.06–1.83] 650 (48.0) 665 (50.9) 1.16 [0.97–1.37] 0.26
Decrease of >5* 175 (34.2) 159 (28.6) 0.77 [0.58–1.03] 432 (31.9) 385 (29.5) 0.87 [0.73–1.05] 0.48
Change in NYHA functional class at 52 weeks
Odds ratio for improvement† 81/425 (19.1) 109/479 (22.8) 1.25 [0.88–1.78] 222/1,110 (20.0) 251/1,057 (23.7) 1.32 [1.06–1.66] 0.81
Odds ratio for worsening† 71/425 (16.7) 78/479 (16.3) 0.97 [0.68–1.38] 208/1,110 (18.7) 164/1,057 (15.5) 0.78 [0.62–0.98] 0.31
Values are n (%), hazard ratio (95% confidence interval), n, absolute difference  SD, odds ratio [95% confidence interval], or n/N (%). The proportions of responders were compared between treatment
groups by using a logistic regression model including for age, baseline eGFR, baseline KCCQ value, region, baseline diabetes status, sex, baseline left ventricular ejection fraction, treatment arm, baseline use
of MRA, and treatment arm by baseline use of MRA interaction. Multiple imputations were used to impute missing data. The observed number and proportion of responders, OR between treatment groups,
95% CI, and 2-sided p value estimated from each imputed dataset were combined by using Rubin’s rule, and the combined results are presented. The p values and 95% CIs presented in this report have not
been adjusted for multiplicity, and therefore, inferences drawn from these statistics may not be reproducible. *Patients who died before 52 weeks are considered as having not improved or deteriorated.
Missing scores are imputed for surviving patients. Ceiling effects were managed as follows: if a patient had a baseline value of #5 points, he or she was defined as having a 5-point deterioration if the value
was #5 points at 52 weeks; conversely, if a patient had a baseline value of $95 points, he or she was defined as having a 5-point improvement if the value was $95 points at 52 weeks. †Logistic regression
analysis adjusted for age, baseline eGFR, treatment arm, region, baseline diabetes status, sex, baseline left ventricular ejection fraction, baseline NYHA functional class, baseline use of MRA, and baseline use
of MRA by treatment interaction. No improvement/deterioration was imputed for patients who died or had missing data due to being lost to follow-up or withdrawal of consent at 52 weeks.
Abbreviations as in Table 1.
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Other clinical features are shown in Table 1. MRA
users were prescribed spironolactone in 2,091 (78.6%)
and eplerenone in 570 (21.4%) patients. Of the
patients treated with an MRA, 1,355 were randomized
to placebo and 1,306 to empagliflozin; of the patients
not treated with an MRA, 512 were randomized to
placebo and 557 to empagliflozin.
EFFECT OF EMPAGLIFLOZIN ON MEASURES OF
EFFICACY ACCORDING TO MRA USE. With respect to
heart failure and renal outcomes, when compared
with placebo, the effect of empagliflozin was similar
regardless of the use of an MRA at baseline (Table 2,
Figure 1). The hazard ratios for the effect of empagli-
flozin on the primary composite outcome
of cardiovascular death or hospitalization for heart
failure were 0.75 (95% CI: 0.63 to 0.88) and 0.76
(95% CI: 0.59 to 0.97) in MRA users and MRA non-
users, respectively (interaction p ¼ 0.93) (Figure 1).
The hazard ratios for the effect of empagliflozin on
total hospitalizations for heart failure were 0.71
(95% CI: 0.56 to 0.89) and 0.69 (95% CI: 0.48 to
0.97), respectively (interaction p ¼ 0.88). Addition-
ally, baseline use of an MRA did not influence the
effect of empagliflozin on health status (assessed
by KCCQ score), New York Heart Association
(NYHA) functional class, and the severity ofheart failure hospitalizations (i.e., hospitalizations
requiring intensive care or receiving treatment
with intravenous positive inotropic drugs, vaso-
pressor agents, or mechanical interventions) (Table 2,
Supplemental Table 1).
The use of MRAs also did not influence the effect of
empagliflozin to retard the worsening of renal func-
tion during double-blind therapy. As compared with
placebo, empagliflozin slowed the rate of decline in
eGFR in both MRA users and nonusers: þ1.55  0.39 in
MRA users and þ2.19  0.59 in MRA nonusers
(interaction p ¼ 0.36) (Table 2). The use of MRAs did
not influence the effect of empagliflozin on the
composite of serious adverse renal outcomes (inter-
action p ¼ 0.18), although the number of events in
MRA nonusers was small (<25 events) (Table 2).
In contrast, for cardiovascular death and all-cause
mortality, the hazard ratios for the effect of empa-
gliflozin versus placebo appeared to be directionally
different for MRA users and nonusers. The hazard
ratio for the effect of empagliflozin was 0.82 (95% CI:
0.65 to 1.05) in MRA users and 1.19 (95% CI: 0.82 to
1.71) in MRA nonusers (interaction p ¼ 0.10). Simi-
larly, for all-cause mortality, the hazard ratios for the
effect of empagliflozin versus placebo were 0.84
(95% CI: 0.68 to 1.03) in MRA users and 1.15 (95% CI:
0.84 to 1.59) in MRA nonusers (interaction p ¼ 0.098)
(Figure 2, Table 2).
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Interaction p value: 0.9345
Interaction p value: 0.8782
HR: 0.75
(95% CI: 0.63 to 0.88)*
180 630 720 810
512
Patients at risk
464 171228296372448 122 72 40
557
Placebo
Empagliflozin 534 213291364446505 150 94 44
1,355
Patients at risk
1,251 4406268129731,164 288 152 69
1,306
Placebo
Empagliflozin 1,229 4326188089781,172 273 137 57
Study Day
No MRA at Baseline MRA at Baseline
No MRA at Baseline
A
B MRA at Baseline
Placebo Empagliflozin
Placebo Empagliflozin
(A) Time-to-first-event analysis of the effect of empagliflozin on cardiovascular death or hospitalizations for heart failure, according to use of mineralocorticoid re-
ceptor antagonist at baseline. (B) Effect of empagliflozin on total (first and recurrent) hospitalizations for heart failure, according to use of mineralocorticoid-receptor
antagonist at baseline using a joint frailty model. *Model includes age, baseline estimated glomerular filtration rate, region, baseline diabetes status, sex, baseline left
ventricular ejection fraction, treatment, baseline use of MRA, and treatment by baseline use of MRA interaction. CI ¼ confidence interval; HR ¼ hazard ratio;
MRA ¼ mineralocorticoid receptor antagonist.
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1401EFFECT OF EMPAGLIFLOZIN ON UTILIZATION OF
MRAs FOLLOWING RANDOMIZATION. Among the
1,069 MRA nonusers at baseline (512 on placebo and
557 on empagliflozin), those randomized to empagli-
flozin were 35% less likely to be initiated on treat-
ment with an MRA during the follow-up (122 on
placebo and 90 on empagliflozin) (hazard ratio: 0.65;
95% CI: 0.49 to 0.85; p ¼ 0.0019). This differential
post-randomization utilization was apparent shortly
following the initiation of double-blind treatment
(Table 3, Central Illustration). Conversely, among the
2,661 MRA users at baseline (1,355 in the placebo and
1,306 in the empagliflozin group), those randomizedto empagliflozin were less likely to discontinue or
interrupt treatment with MRAs during double-blind
therapy following randomization (210 in the placebo
and 164 in the empagliflozin group) (hazard ratio:
0.78; 95% CI: 0.64 to 0.96; p ¼ 0.018).
INFLUENCE OF MRA ON THE EFFECT OF EMPAGLIFLOZIN
ON VITAL SIGNS, BIOMARKERS, AND SAFETY. The
effects of empagliflozin on systolic blood pressure,
body weight, glycated hemoglobin, uric acid,
NT-proBNP, and hematocrit were not influenced by
use of MRA at baseline (Supplemental Table 2).
When MRA users and nonusers were combined, the
risk of hyperkalemia was lower in the empagliflozin
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Interaction
p valuesRate/100 PY%n/Nn/N Rate/100 PY%
12.4
15.6
Favors Empagliflozin Favors Placebo
The p values and 95% CIs presented in this report have not been adjusted for multiplicity, and therefore, inferences drawn from these statistics may not be repro-
ducible. PY ¼ person-years; other abbreviations as in Figure 1.
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1402than in the placebo group (Table 4). The effect of
empagliflozin was particularly noteworthy in pre-
venting the occurrence of severe hyperkalemia
(hazard ratio: 0.70; 95% CI: 0.47 to 1.04); however,
the effect of empagliflozin on the risk of severe
hyperkalemia did not differ in MRA users and non-
users at baseline (interaction p ¼ 0.56). For all other
assessments, the use of MRA at baseline did not
influence the safety profile of empagliflozin
(Supplemental Table 3).
DISCUSSION
In large-scale randomized controlled trials in patients
with type 2 diabetes, with chronic kidney disease, and





Initiation of MRA in patients not receiving
an MRA at baseline
122/512 (23.8) 21.2
Discontinuation or interruption of MRA
in patients receiving an MRA at baseline
210/1,355 (15.5) 13.2
CI ¼ confidence interval; HR ¼ hazard ratio; MRA ¼ mineralocorticoid receptor antagonSGLT2 inhibitors have had a remarkably consistent
effect to reduce the risk of hospitalizations for heart
failure and to slow the progression of renal disease
(3–9). Most patients in the cardiovascular outcomes
trials with type 2 diabetes were not treated with
MRAs.
In the original publications of both the DAPA-HF
trial and EMPEROR-Reduced, background use of
MRAs at baseline did not influence the effect of
dapagliflozin and empagliflozin on the primary com-
posite of cardiovascular death or hospitalization for
heart failure (3,4). However, more data are needed to
assess whether the use of spironolactone or epler-
enone might influence the effects of SGLT2 inhibitors
on other measures of efficacy or on safety. The cur-
rent study demonstrates that the use of MRAs atin the Placebo and Empagliflozin Groups
Empagliflozin





90/557 (16.2) 13.2 0.65 (0.49–0.85) 0.0019
164/1,306 (12.6) 10.7 0.78 (0.64–0.96) 0.018
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Ferreira, J.P. et al. J Am Coll Cardiol. 2021;77(11):1397–407.
Among MRA nonusers, the empagliflozin group was 35% less likely than the placebo group to initiate treatment with an MRA following
randomization. Among MRA users, the empagliflozin group was 22% less likely than the placebo group to discontinue treatment with an
MRA following randomization. (A) Time to initiation of MRA treatment in patients not using an MRA at baseline. (B) Time to discontinuation or
temporary interruption of MRA in patients using MRA at baseline. *Model includes age, baseline estimated glomerular filtration rate, region,
baseline diabetes status, sex, baseline left ventricular ejection fraction, and treatment. CI ¼ confidence interval; HR ¼ hazard ratio;
MRA ¼ mineralocorticoid receptor antagonist.
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TABLE 4 Effect of Empagliflozin on the Occurrence of Hyperkalemia















































































Rate is expressed as events per 100 person-years. *Analysis performed in patients with potassium level of <5.5 mmol/L at baseline only. †Analysis performed in patients with potassium level of <6.0 mmol/L
at baseline only. Shown are adverse events up to 7 days and serum potassium levels up to 3 days following discontinuation of the study medication.
Abbreviations as in Table 3.
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1404randomization did not influence the benefits of
empagliflozin to reduce the number or severity of
heart failure hospitalizations and to improve health
status (as assessed by the KCCQ) or functional capac-
ity (as assessed by NYHA functional class). Further-
more, empagliflozin slowed the decline in glomerular
filtration rate and reduced the risk of serious adverse
renal outcomes similarly in patients who did or did
not receive spironolactone or eplerenone, although
the number of adverse renal events in MRA nonusers
was small. Finally, the use of MRAs did not modify the
effect of empagliflozin on physiological measures or
biomarkers that reflect the actions of SGLT2 in-
hibitors, and MRA use did not adversely affect the
safety of the drug when given to patients with heart
failure and a reduced ejection fraction.
Nevertheless, empagliflozin had a meaningful in-
fluence on the utilization of MRAs following
randomization in 2 important ways. First, patients in
the empagliflozin group who had not been treated
with spironolactone or eplerenone at baseline were
35% less likely to be initiated on an MRA following
randomization; that is, among nonusers of an MRA at
baseline, 23.8% of placebo-treated patients but only
16.2% of empagliflozin-treated patients were initiated
on therapy with an MRA during double-blind follow-
up. This differential utilization may have been related
to the benefits of empagliflozin on health status and
NYHA functional class, which may have diminished
clinical pressures (on the part of both the patient
and the physician) to intensify treatments with
drugs known to be effective for the treatment of heart
failure. An initial increase in serum creatinine
(related to an effect on intrarenal hemodynamics)
in empagliflozin-treated patients may have also
discouraged initiation of treatment with an MRA (10).Second, patients in the empagliflozin group who had
been treated with spironolactone or eplerenone were
22% less likely to discontinue treatment with these
drugs following randomization; that is, among users
of an MRA at baseline, 15.5% of placebo-treated
patients, but only 12.6% of empagliflozin-treated pa-
tients stopped or interrupted treatment with an MRA.
This differential utilization may have been related to
favorable effects of empagliflozin to mitigate the
occurrence of hyperkalemia and to prevent wors-
ening renal function during long-term treatment,
because increases in serum creatinine or potassium
levels can cause physicians to withhold treatment
with MRAs in patients who are receiving these drugs
(11–13). Additionally, because hospitalizations are
known to trigger changes in background therapy, it is
possible that the lower rates of hospitalizations for
heart failure in patients randomized to empagliflozin
might have contributed to our finding of lower rates
of initiation or discontinuation of MRAs in the
empagliflozin group.
The potential for an effect of empagliflozin to
reduce the risk of hyperkalemia is noteworthy,
because a similar finding has been reported with the
use of dapagliflozin in the patients with heart failure
and a reduced ejection fraction who were enrolled in
the DAPA-HF trial (14). In that trial, the effect of
SGLT2 inhibition to reduce the risk of serum potas-
sium of >6.0 mmol/l was particularly notable in pa-
tients who were treated with an MRA at baseline, with
a 50% relative reduction, an effect size that was
similar to the 36% reduction in this risk seen in the
EMPEROR-Reduced, although the latter was not
statistically significant. Of note, SGLT2 inhibitors
appeared to have little effect on serum potassium in
patients with type 2 diabetes without heart failure,
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were receiving MRAs (15). The mechanism by which
SGLT2 inhibitors may selectively interfere with MRA-
induced hyperkalemia is not known. Interestingly, a
similar effect has been reported with the use of
sacubitril/valsartan in patients with heart failure and
a reduced ejection fraction (16).
Might the effect of empagliflozin to promote dif-
ferential utilization of MRAs following randomization
have confounded the analyses of survival in
EMPEROR-Reduced? As seen in Table 3, when
compared with the empagliflozin group, 32 additional
patients in the placebo group who were nonusers of
an MRA at baseline were initiated on treatment with
an MRA, and the differential enrichment was
apparent almost immediately after the start of
double-blind therapy. Because MRAs reduce mortal-
ity in heart failure with a reduced ejection fraction
(1,2), it is likely that lives might have been saved
preferentially in the placebo group, contributing to
the apparent excess estimate of hazard in
empagliflozin-treated patients who were MRA non-
users at randomization. Conversely, when compared
with the placebo group, 46 additional patients in the
empagliflozin group who were users of an MRA at
randomization were maintained on treatment with an
MRA, potentially contributing to the lower hazard of
death observed in empagliflozin-treated patients who
were MRA users at randomization. Therefore, differ-
ential post-randomization utilization of MRAs in both
MRA users and nonusers may help explain our finding
of a possible qualitative interaction between baseline
MRA use and the effect of empagliflozin on survival
(interaction p ¼ 0.10, unadjusted for multiple com-
parisons). It is important to note that post-
randomization differential enrichment is not meth-
odologically accounted for in a conventional
intention-to-treat analysis (17,18).
If the differential utilization of MRAs following
randomization exerted an influence on estimates of a
treatment effect on mortality, it is possible that dif-
ferences that occurred by chance in the use of MRAs at
the time of randomization might also have influenced
the estimates of the effect of empagliflozin.
EMPEROR-Reduced did not stratify randomization
according to the use of MRAs, and by the play of
chance, patients prescribed an MRA at baseline were
more likely to be randomized to placebo, a difference
that involved 49 patients. Conversely, in DAPA-HF,
the use of MRAs was (by chance) more frequent in
the patients randomized to dapagliflozin than placebo
(by 22 patients) (3). Because randomization does not
ensure balance of all baseline factors that can influ-
ence outcomes, imbalances in treatments that canaffect outcomes can affect reported estimates of the
size of treatment effects. Accordingly, it is important
to adjust for prognostically relevant baseline cova-
riates, and such adjustment (even when performed
post hoc) can help reconcile conflicting reports of the
efficacy of similar treatments (19).
STUDY STRENGTHS AND LIMITATIONS. The current
study should be interpreted in light of its strengths
and limitations. The use of an MRA at baseline was
included as 1 of 12 pre-specified subgroups, but many
of the analyses reported herein are post hoc, as is
common in secondary manuscripts following the
publication of the primary results of a large-scale
trial. Given the exploratory nature of this report, we
did not perform correction for multiplicity of tests.
Notwithstanding, our finding that the use of an MRA
did not influence the effects of empagliflozin on most
variables is consistent with similar findings in the
DAPA-HF trial (20). However, it is not known if dif-
ferential enrichment of MRA use following randomi-
zation was seen in the DAPA-HF trial. Finally, the
clinical impact of the differential use of MRAs at
baseline and following randomization is dependent
on assumptions about the magnitude of the survival
advantage of MRAs and the duration of differential
use, and these complexities undermine our ability to
estimate the potential for post-randomization bias
with a reasonable degree of precision.
CONCLUSIONS
With respect to adverse heart failure and renal out-
comes, the use of an MRA did not influence the ef-
fects of empagliflozin in patients with heart failure
and a reduced ejection fraction. This finding indicates
that MRAs and SGLT2 inhibitors can be usefully
combined to reduce morbidity and mortality and
improve symptoms and health status without con-
cerns of an adverse interaction. The observation that
treatment with empagliflozin may influence physi-
cian decision making regarding the utilization of
MRAs may have important implications for the design
and analysis of large-scale trials where background
therapy with life-prolonging drugs is not tightly
controlled and may confound estimates of a treat-
ment effect of the study medication. In the clinical
setting, a favorable symptomatic response to SGLT2
inhibition should not obviate the use of MRAs by
practitioners. Furthermore, the possibility that the
use of SGLT2 inhibitors may enhance the ability of
patients to be maintained on treatment with an MRA
provides further support for the value of combining
these 2 classes of drugs to improve outcomes in pa-
tients with heart failure.
PERSPECTIVES
COMPETENCY IN PATIENT CARE: In EMPEROR-
Reduced, concomitant administration of empagliflozin
with MRAs to patients with heart failure was well
tolerated, and MRAs did not modify the effect of
empagliflozin on cardiac or renal outcomes.
TRANSLATIONAL OUTLOOK: Elucidating the
mechanisms by which empagliflozin exerts beneficial
effects in patients with heart failure with or without
concomitant MRA therapy requires further study.
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